BACK

Nitin Lath

Nitin Lath

Managing Director

Mumbai Office  |  nitin.lath@torreya.com   |   +91 99-8755-6055

Nitin Lath, a Managing Director in Torreya’s Mumbai office, has two decades of investment banking experience analyzing and advising Indian companies across all life sciences sectors.

Before joining Torreya in 2016, Nitin led the healthcare banking division of IDFC Securities and was a member of life sciences investment banking teams at Avendus Capital and Yes Bank Ltd. Earlier in his career, while at IDBI Bank Ltd., he was responsible for the life sciences credit portfolio, and he was a member of the structured finance team at ICICI Bank Ltd.

Highlights of Nitin’s life sciences transaction work include advising Dr. Reddy’s on its acquisition of drug-delivery company Octoplus, advising Shasun Pharma in its merger with Strides, advising Greater Pacific Capital on the sale of its stake in Torrent, and advising Bain Capital on its acquisition of Blackstone’s stake in Emcure Pharma.

Nitin earned his B.A in commerce from Mumbai University. He is also a Chartered Accountant from ICAI and a Chartered Financial Analyst. Nitin is fluent in English and Hindi.

Selected Transactions

Zydus
Sale of domestic brands to
Integrace
September 2021
Relisys
Investment by
Siguler Guff
$13.5 million
August 2021
Hemmo
Sale of 100%
equity stake to
Piramal Pharma Solutions
$106 million + milestones
June 2021
Rubicon Research
Majority recap by
General Atlantic Partners
$125 million
April 2019
Motilal Oswal
and
InvAscent
purchase of majority stake in
Symbiotec
undisclosed
December 2018
DRL
Divestment of Leiden, Netherlands facility to
Delpharm
December 2022
Marksans
Acquisition of bulk formulation manufacturing facility from
Teva India
October 2022
Accumax
Investment by
Creador_Invascent
$68 million
June 2022
Yapan Bio
Investment by
Piramal Pharma Solutions
December 2021
DRL
Sale of U.S. and Canadian rights for ELYXYB to
BDSI
August 2021
Biological E
Acquisition of Akorn India Limited, a subsidiary of
Akorn
August 2020
Glenmark
collaboration for its gynecological business in Nepal and India with
Integrace
January 2020
Biological-E
BE Vaccines SAS sale to Clean Cells, a portfolio company of
Archimed
Undisclosed
March 2019
Neuland Laboratories
Acquisition of
API facility from
Arch Pharma
December 2017
Sandoz
Sale of selected
generic brands to
Samara Capital
June 2017
Neuland Laboratories
Sale of stake of
InvAscent
$35 million
Joint Sell-Side Advisor
May 2017
Sandoz
Sale of India women's health business to
Torrent Pharma
April 2017
Rubicon Research
Sale of equity stake to
Everstone Group
$33 million
November 2016